Authors

Controlled Clinical Trials in Sub-Saharan Africa: A Winning Value Proposition

Persistent recruitment delays, high dropout rates, and missed timelines continue to slow global clinical trials, while data show that sub-Saharan Africa offers a largely untapped opportunity with established research capacity, large patient pools, and strong enrollment and retention performance.

Accelerating Breakthroughs with Synthetic Clinical Trial Data

The emergence of AI-powered simulants in improving study efficiency.

Sponsor Oversight in an Outsourced Trial: What Good Looks Like and How to Evidence It

Sponsor oversight of outsourced CRO work is often robust in practice but fails inspection because oversight decisions are fragmented across systems and lack an audit trail, requiring sponsors to document oversight as a connected operating system with clear decision records, escalation pathways, and issue resolution from start to finish.

Future Proofing Your Outsourcing Strategy: How to Stay Agile in a Fast-Moving Clinical Trial Ecosystem

A blend of FSO and FSP models in the landscape of artificial intelligence can ensure CROs stay up to date with the unique demands of industry.

Utilizing Tech Tools to Accelerate Drug Development

In a decentralized, digitally enabled clinical trial environment, conventional approaches to data analysis are evolving as sponsors utilize technological tools in new ways to ensure compliance with global standards, mitigate risk, and bring life-changing therapies to patients faster.

Realtime Electronic Data Capture at Investigator Sites: Laboratory Data and Beyond

Balancing Scientific Innovation with Lived Experience: A Strategic Imperative in Pediatric Clinical Trials

Pediatric trial participation shapes children's and caregivers' long-term psychological outcomes, yet protocol design often overlooks experience as a variable affecting recruitment, retention, and data integrity—a gap increasingly recognized by regulators and quality standards

Reprioritizing DNA Damage Response: Leveraging Lessons Learned to Develop Next-Generation Inhibitors

Advancements in this field have the potential to transform cancer care and improve quality of life for patients.

Validity, Reliability, and Regulatory Considerations for Consumer Devices in Clinical Research Data Collection

Consumer-grade wearables offer promise for reducing trial burden and improving engagement, but accuracy and reliability vary substantially by device, measurement, and population, requiring rigorous fit-for-purpose validation and careful endpoint selection before integration into regulated research.

The Evolution of Preclinical CRO Strategic Partnerships: From Transactional Services to Value-Driven Ecosystems in 2026

As the life sciences industry continues to evolve, the ability to effectively manage and leverage preclinical CRO partnerships is set to become a defining characteristic of successful biopharma companies.

Detecting Fraud in Clinical Trials Using Statistical Data Monitoring

Exploring stat-based testing for variables that identify deliberate data manipulation in clinical trials.

Language of Medicine: Translating Between German and English

The complexities behind these translations require specialized personnel who are nuanced in both medical cultures.

Putting Collective Insights Into Action to Advance Cancer Care: Key Examples From ASCO 2025

At ASCO 2025, clinical operations leaders gained critical insights into how AI tools, bispecific antibodies, and evolving treatment paradigms are reshaping trial design, endpoint selection, and patient stratification.

2025 Veeva R&D and Quality Summit: Effectively Utilizing Clinical Reference Data

Explore the challenges sponsors and CROs face in maintaining clinical reference data, uncover the hidden costs of traditional upkeep models, and see how integrated data solutions can streamline operations across the clinical ecosystem.

Harnessing Data Analytics and AI for Clinical Trials

Balancing these tools with operational efficiencies can aid CROs in meeting the evolving needs of sponsors.

Scaling eSource-Enabled Clinical Trials: Hospital Perspectives

The challenges, opportunities, and strategic outlook for oncology research centers.

Accelerating Breakthroughs with Synthetic Clinical Trial Data

The emergence of AI-powered simulants in improving study efficiency.

Crossing the Digital Chasm: Site Burden Isn’t an Excuse Anymore

You've Been Spending Recruitment Money at the Wrong End of the Funnel

Under-enrollment isn't news to teams running oncology trials, and the instinct is to spend more on reach. The evidence, however, says the biggest leak is something else entirely and that most recruitment budgets focus on the least valuable part of the problem.

Navigating the Adoption of Biomarker-Informed Trial Enrollment Beyond Oncology

Biomarker-informed trial enrollment appears straightforward for identifying responders and optimizing efficiency, but failures to account for demographic variation in cut-off selection, causality versus correlation, and composite biomarker complexity risk excluding viable patients and exacerbating disparities.

Q&A: Strategies for Successful Global Clinical Trial Delivery

In this Q&A, Randa Wahid of Indero, and Lyn Mursalo, a freelance clinical research professional, share how sponsors and CROs can build collaborative partnerships, navigate global trial complexities, and apply practical strategies to deliver studies on time and with quality.

Beyond Regulatory Intelligence: How an FSP PV Partner Helps Ensure Global Compliance

Support from these partners can aid drug and medical device developers in keeping up with the evolving regulatory landscape.

The Career They Didn't Train For: Rethinking Early-Career Burnout in Clinical Research

Clinical research coordinators face early burnout driven by gaps between job expectations and operational reality, inadequate mentorship structures, and fragmented technology environments that compound insufficient onboarding and deplete resources needed to sustain engagement.

Clinical Trials in 2026: Platformization, AI Fluency, and the Redrawing of the Value Chain

The clinical trial ecosystem is entering a phase of consolidation and reinvention driven by the collapse of boundaries between functions, data, and even companies themselves.

Saving the Last Mile of Medicine

Sample integrity and traceability often fail not because of science but because clinical trials rely on manual processes and fragmented systems that obscure problems until samples are already compromised.

From Perspective to Action: Addressing the Real Cost Pressures in Clinical Trial Budgeting

Static budgeting models and one-size-fits-all fair market value approaches create visibility gaps around inflation and true site costs, but regional frameworks, standardized costing toolkits, and accountability metrics can rebuild trust and replace defensive negotiations with transparency.

Setting the Limits of Autonomy with Autonomous Agents for Clinical Research

As pharma wrestles with whether to trust fully autonomous AI, semi-autonomous agents are emerging as a safer middle ground that reduces manual work, eliminates white space in clinical development, and accelerates trial timelines without compromising patient safety.

From Participation to Understanding: Reframing Engagement in Clinical Trials

Participant engagement depends more on clarity and understanding than on gamification or incentives, requiring engagement embedded into trial workflows as a core design component rather than a peripheral consideration